CoChat
Sign Up
Cited by 57Antifungal resistance and susceptibilityFungal and yeast genetics researchFungal Plant Pathogen Control

LY303366 Exhibits Rapid and Potent Fungicidal Activity in Flow Cytometric Assays of Yeast Viability

Open access
Green, Lisa J., Marder, Philip, Mann, Larry L., Chio, Li-Chun, Current, William L.·1999·Antimicrobial Agents and Chemotherapy
DOI 10.1128/aac.43.4.830PMC PMC89213
Open this paper in CoChat — free account

Abstract

LY303366 is a semisynthetic analog of the antifungal lipopeptide echinocandin B that inhibits (1,3)-β- d -glucan synthase and exhibits efficacy in animal models of human fungal infections. In this study, we utilized flow cytometric analysis of propidium iodide uptake, single-cell sorting, and standard microbiological plating methods to study the antifungal effect of LY303366 on Saccharomyces cerevisiae and Candida albicans . Our data indicate that an initial 5-min pulse treatment with LY303366 caused yeasts to take up propidium iodide and lose their ability to grow. Amphotericin B and cilofungin required longer exposure periods (30 and 180 min, respectively) and higher concentrations to elicit these fungicidal effects. These two measurements of fungicidal activity by LY303366 were highly correlated ( r > 0.99) in concentration response and time course experiments. As further validation, LY303366-treated yeasts that stained with propidium iodide were unable to grow in single-cell-sorted cultures. Our data indicate that LY303366 is potent and rapidly fungicidal for actively growing yeasts. The potency and rapid action of this new fungicidal compound suggest that LY303366 may be useful for antifungal therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.43.4.830

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 31

  1. [1]Bartlett M S, Current W L, Goheen M P, Boylan C J, Lee C H, Shaw M M, Queener S F, Smith J W. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother. 1996;40:1811–1816. doi: 10.1128/aac.40.8.1811. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  2. [2]Beaulieu D, Tang J, Yan S B, Vessels J M, Radding J A, Parr T R., Jr Characterization and cilofungin inhibition of solubilized Aspergillus fumigatus (1,3)-β-d-glucan synthase. Antimicrob Agents Chemother. 1994;38:937–944. doi: 10.1128/aac.38.5.937. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  3. [3]Current W, Turner W. Echinocandin antifungal agents. In: Strohl W, editor. Biotechnology of antibiotics. New York, N.Y: Marcel Dekker, Inc.; 1997. pp. 315–334. [Google Scholar]
  4. [4]Davey H M, Kell D B. Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses. Microbiol Rev. 1996;60:641–696. doi: 10.1128/mr.60.4.641-696.1996. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  5. [5]Debono M, Gordee R S. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994;48:471–497. doi: 10.1146/annurev.mi.48.100194.002351. [DOI] [PubMed] [Google Scholar] · DOI
  6. [6]Debono M, Turner W W, LaGrandeur L, Burkhardt F J, Nissen J S, Nichols K K, Rodriguez M J, Zweifel M J, Zeckner D J, Gordee R S, et al. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J Med Chem. 1995;38:3271–3281. doi: 10.1021/jm00017a012. [DOI] [PubMed] [Google Scholar] · DOI
  7. [7]Diaper J P, Tither K, Edwards C. Rapid assessment of bacterial viability by flow cytometry. Appl Microbiol Biotechnol. 1992;38:268–272. doi: 10.1007/BF00174481. [DOI] [PubMed] [Google Scholar] · DOI
  8. [8]Gallis H A, Drew R H, Pickard W W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar] · DOI
  9. [9]Gordee R S, Zeckner D J, Howard L C, Alborn W E, Jr, Debono M. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann N Y Acad Sci. 1988;544:294–309. doi: 10.1111/j.1749-6632.1988.tb40415.x. [DOI] [PubMed] [Google Scholar] · DOI
  10. [10]Green L, Petersen B, Steimel L, Haeber P, Current W. Rapid determination of antifungal activity by flow cytometry. J Clin Microbiol. 1994;32:1088–1091. doi: 10.1128/jcm.32.4.1088-1091.1994. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  11. [11]Krishnarao T V, Galgiani J N. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother. 1997;41:1957–1960. doi: 10.1128/aac.41.9.1957. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  12. [12]Kurtz M B, Heath I B, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-d-glucan synthase. Antimicrob Agents Chemother. 1994;38:1480–1489. doi: 10.1128/aac.38.7.1480. . (Erratum, 38:2516.) [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  13. [13]Lloyd D, Hayes A J. Vigour, vitality and viability of microorganisms. FEMS Microbiol Lett. 1995;133:1–7. [Google Scholar]
  14. [14]Martin E, Maier F, Bhakdi S. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother. 1994;38:1331–1338. doi: 10.1128/aac.38.6.1331. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  15. [15]Martin E, Schlasius U, Bhakdi S. Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum. Med Microbiol Immunol. 1992;181:117–126. doi: 10.1007/BF00202051. [DOI] [PubMed] [Google Scholar] · DOI
  16. [16]Moore C B, Oakley K L, Denning D W. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1997. In vitro activity of LY303366 compared with fluconazole, flucytosine and amphotericin B against Candida spp., abstr. F-67; p. 157. [Google Scholar]
  17. [17]Odds F C. Resistance of clinically important yeasts to antifungal agents. Int J Antimicrob Agents. 1996;6:145–147. doi: 10.1016/0924-8579(95)00048-8. [DOI] [PubMed] [Google Scholar] · DOI
  18. [18]Ordonez J V, Wehman N M. Amphotericin B susceptibility of Candida species assessed by rapid flow cytometric membrane potential assay. Cytometry. 1995;22:154–157. doi: 10.1002/cyto.990220213. [DOI] [PubMed] [Google Scholar] · DOI
  19. [19]Petersen B H, Green L, Steimel L, Hyslop D, Current W L. Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1993. Use of flow cytometry for determination of minimal exposure time for effective antifungal activity of LY303366 and other antifungal compounds, abstr. 362; p. 185. [Google Scholar]
  20. [20]Pfaller M A, Messer S A, Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob Agents Chemother. 1997;41:763–766. doi: 10.1128/aac.41.4.763. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  21. [21]Pore R S. Amphotericin B synergy testing by the FCST. Curr Microbiol. 1992;24:171–177. [Google Scholar]
  22. [22]Pore R S. Antibiotic susceptibility testing of Candida albicans by flow cytometry. Curr Microbiol. 1990;20:323–328. [Google Scholar]
  23. [23]Rennie R, Sand C, Smith S. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1996. In vitro activity of antifungal agent LY303366 against Candida species, other yeasts and Aspergillus species, abstr. F45; p. 107. [Google Scholar]
  24. [24]Taft C S, Stark T, Selitrennikoff C P. Cilofungin ( LY121019) inhibits Candida albicans (1-3)-β-d-glucan synthase activity. Antimicrob Agents Chemother. 1988;32:1901–1903. doi: 10.1128/aac.32.12.1901. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  25. [25]Tang J, Parr T R., Jr W-1 solubilization and kinetics of inhibition by cilofungin of Candida albicans (1,3)-β-d-glucan synthase. Antimicrob Agents Chemother. 1991;35:99–103. doi: 10.1128/aac.35.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  26. [26]Uzun Ö, Kocagöz S, Çetinkaya Y, Arikan S, Ünal S. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother. 1997;41:1156–1157. doi: 10.1128/aac.41.5.1156. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  27. [27]Vanden Bossche H, Willemsens G, Marichal P. Anti-Candida drugs—the biochemical basis for their activity. Crit Rev Microbiol. 1987;15:57–72. doi: 10.3109/10408418709104448. [DOI] [PubMed] [Google Scholar] · DOI
  28. [28]Wade J C. Treatment of fungal and other opportunistic infections in immunocompromised patients. Leukemia. 1997;11(Suppl. 4):S38–S39. [PubMed] [Google Scholar]
  29. [29]Zeckner D, Butler T, Boylan C, Boyll B, Lin Y, Raab P, Schmidtke J, Current W. Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1993. LY303366, activity in a murine systemic candidiasis model, abstr. 365; p. 186. [Google Scholar]
  30. [30]Zeckner D, Butler T, Boylan C, Boyll B, Watson P, Current W. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1995. In vitro evaluation of LY303366 against Candida spp. clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis, abstr. F98; p. 130. [Google Scholar]
  31. [31]Zelenitsky S, Karlowsky J, Hoban D, Laing N, Balko T, Kabani A, Turik M, Zhanel G. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1997. Activity of an investigational echinocandin, LY303366 against fluconazole susceptible and resistant Candida albicans in a multiple dose in vitro pharmacodynamic model, abstr. F-72; p. 158. [Google Scholar]

Cited by

Sorted by citations

Authors
Green, L. J., Marder, P., Mann, L. L., Chio, L.-C., & Current, W. L.
Affiliations
Eli Lilly (United States) (US)
Venue
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Published
1999-04
Volume
43
Issue
4
Pages
830-835
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
DOI
10.1128/aac.43.4.830
PMC
PMC89213
OpenAlex
W2160355967
Cited by
57
References
0
Citations by year
2025: 2 · 2024: 2 · 2023: 1 · 2021: 3 · 2020: 2 · 2016: 1 · 2015: 2 · 2014: 1 · 2012: 1
FWCI
2.73
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Keywords
antifungal lipopeptides, fungicidal activity, Saccharomyces cerevisiae, Candida albicans, propidium iodide uptake, yeast viability, amphotericin B, antifungal therapy
MeSH terms
Anidulafungin, Antifungal Agents, Candida albicans, Cell Division, Cell Separation, Flow Cytometry, Humans, Indicators and Reagents, Microbial Sensitivity Tests, Peptides, Cyclic, Propidium, Saccharomyces cerevisiae, Time Factors, Echinocandins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review